

TRANSCRIPTIONAL REGULATION OF HUMAN UDP- GLUCURONOSYLTRANSFERASES

Dione Anne Gardner-Stephen

B. Biotech. (Hons)

Department of Clinical Pharmacology

Faculty of Health Sciences, School of Medicine

Flinders University

**A thesis submitted in fulfilment of the requirements for the
degree of Doctor of Philosophy**

2008

TABLE OF CONTENTS

List of Figures	viii
List of Tables	xi
Summary	xii
Declaration	xiv
Acknowledgements	xv
Publications arising directly from this thesis	xvii
Additional publications related to this thesis	xvii
Awards in support of this thesis	xviii
Abbreviations	xix
Chapter One: General Introduction	1
1.1 Towards disease prevention and designer therapies	1
1.2 Genetic variation in metabolic pathways; implications for disease susceptibility and treatment	3
1.3 Biotransformation of small lipophilic molecules	5
1.4 Glucuronidation and the UDP-Glucuronosyltransferases	10
1.5 Genomic organisation of the human <i>UGT</i> gene family	14
1.5.1. <i>The human UGT1 locus</i>	14
1.5.2. <i>The human UGT2 locus</i>	16
1.6 UGT substrates	17
1.7 Location and distribution of human UGT gene products	17
1.8 Causes and consequences of variability in UGT expression and activity	23
1.8.1. <i>UGT expression during human development</i>	23
1.8.2. <i>Gender effects on human glucuronidation</i>	26
1.8.3. <i>Xenobiotic exposure and glucuronidation</i>	26
1.8.4. <i>Pregnancy and UGT expression</i>	30
1.8.5. <i>Health and glucuronidation</i>	31
1.8.6. <i>Genetic variation and glucuronidation</i>	33
1.9 Regulation of human <i>UGT</i> genes	43
1.9.1. <i>Transcriptional regulation: transcription factors and co-regulators</i>	43
1.9.2. <i>Gene regulatory elements: the core promoter, the proximal promoter and enhancer elements</i>	45

1.9.3.	<i>Regulation of human UGT genes</i>	47
1.10	Experimental aims	53
Chapter Two: Materials and Methods		55
2.1	Materials	55
2.1.1.	<i>Chemicals and molecular biology reagents</i>	55
2.1.2.	<i>General buffers</i>	59
2.1.3.	<i>Eukaryotic and prokaryotic cell lines</i>	60
2.1.4.	<i>Mammalian reporter and expression vectors</i>	60
2.1.5.	<i>Cloning vectors</i>	61
2.2	General methods	61
2.2.1.	<i>Maintenance of mammalian cell lines</i>	61
2.2.2.	<i>Bacterial culture and preparation of competent cells</i>	62
2.2.3.	<i>Extraction of total RNA and generation of cDNA</i>	63
2.2.4.	<i>Extraction of genomic DNA from HEK293T cells</i>	65
2.2.5.	<i>Plasmid and BAC preparation</i>	66
2.2.6.	<i>Polymerase chain reaction amplification</i>	68
2.2.7.	<i>Restriction digests, calf intestinal alkaline phosphatase treatment, ligation and transformation</i>	72
2.2.8.	<i>Electrophoresis and quantification of DNA and RNA</i>	74
2.2.9.	<i>Sequencing</i>	75
2.2.10.	<i>Transient transfection of HepG2, Caco-2 and HEK293T cells</i>	75
2.2.11.	<i>Luciferase assay</i>	76
2.2.12.	<i>Preparation of nuclear extracts</i>	77
2.2.13.	<i>Labelling oligonucleotide probes</i>	78
2.2.14.	<i>Electrophoretic mobility-shift assays</i>	79
2.2.15.	<i>Super-shift EMSA</i>	80
2.2.16.	<i>Western blot</i>	80
2.2.17.	<i>Statistical analysis</i>	81
2.3	Cloning of liver-enriched transcription factors	82
2.3.1.	<i>Hepatocyte nuclear factor 1β (HNF1β)</i>	82
2.3.2.	<i>Hepatocyte nuclear factor 4α (HNF4α)</i>	83
2.3.3.	<i>Hepatocyte nuclear factor 6 (HNF6, OneCut 1)</i>	85
2.3.4.	<i>Forkhead box A factors (FoxA, hepatocyte nuclear factor 3 factors)</i>	85
2.3.5.	<i>CAATT enhancer binding protein factors (C/EBP)</i>	86
2.3.6.	<i>Pregnane X receptor (PXR)</i>	86

Chapter Three: *In Vitro* Characterisation of the *UGT1A3*, *UGT1A4* and *UGT1A5* Proximal Promoters 88

3.1 Introduction 88

 3.1.1. *The UGT1A3, UGT1A4 and UGT1A5 gene cluster* 88

 3.1.2. *Expression of UGT1A3, UGT1A4 and UGT1A5* 89

 3.1.3. *Substrates of UGT1A3, UGT1A4 and UGT1A5* 90

 3.1.4. *Regulatory controls of UGT1A3, UGT1A4 and UGT1A5* 92

 3.1.5. *The hepatocyte nuclear factor 1 transcription factor family* 93

 3.1.6. *Aims* 99

3.2 Methods 99

 3.2.1. *Isolation of the UGT1A3-3.3k and UGT1A4-3.4k promoters* 99

 3.2.2. *Generation of UGT1A3 and UGT1A4 promoter deletion constructs and mutants* 102

 3.2.3. *Isolation of the UGT1A5 promoter* 103

 3.2.4. *HNF1 α and HNF1 β expression vectors* 104

 3.2.5. *Transient transfection and luciferase reporter assay* 104

 3.2.6. *Electrophoretic mobility-shift assay* 104

 3.2.7. *Statistical analysis* 105

3.3 Results and discussion 105

 3.3.1. *Basal activities of the UGT1A3, UGT1A4 and UGT1A5 proximal promoters* 105

 3.3.2. *HNF1 is required for basal activity of the UGT1A3 and UGT1A4 proximal promoters* 108

 3.3.3. *HNF1 β can transactivate the UGT1A3 promoter in vitro* 114

 3.3.4. *The UGT1A3 and UGT1A4 proximal promoters differ in their HNF1 responses* 115

 3.3.5. *Factors bound to at least two elements in the UGT1A3 and UGT1A4 promoters co-operate with HNF1 α* 123

3.4 General discussion and summary 126

 3.4.1. *Achievement of aims* 126

 3.4.2. *Future directions* 126

 3.4.3. *Relevance to pharmacogenetics* 128

 3.4.4. *Summary* 129

Chapter Four: HNF1 Transcription Factors are Essential for the *UGT1A9*

Promoter Response to HNF4α	130
4.1 Introduction	130
4.1.1. <i>The UGT1A7, UGT1A8, UGT1A9 and UGT1A10 gene cluster</i>	130
4.1.2. <i>Expression and substrates of UGT1A9</i>	132
4.1.3. <i>Regulatory controls of UGT1A9</i>	133
4.1.4. <i>The hepatocyte nuclear factor 4 transcription factor family</i>	136
4.1.5. <i>Aims</i>	145
4.2 Methods	145
4.2.1. <i>Construction of the pGL3+ reporter plasmid</i>	145
4.2.2. <i>Generation of the UGT1A9-2k reporter construct</i>	146
4.2.3. <i>Generation of UGT1A9 deletion constructs and mutants</i>	150
4.2.4. <i>Isolation of the UGT1A7-5k promoter and generation of pGL3-1A7 -2.5k</i>	151
4.2.5. <i>UGT1A8 and UGT1A10 reporter constructs</i>	152
4.2.6. <i>Isolation of the apoCIII-810/+23 promoter</i>	152
4.2.7. <i>Transcription factor expression vectors</i>	153
4.2.8. <i>Transient transfection and luciferase reporter assay</i>	153
4.2.9. <i>Electrophoretic mobility-shift and super-shift assays</i>	154
4.2.10. <i>In vitro synthesis of transcription factor proteins</i>	154
4.2.11. <i>Western blot</i>	155
4.2.12. <i>Statistical analysis</i>	155
4.3 Results and discussion	156
4.3.1. <i>The UGT1A9 proximal promoter responds strongly to over-expression of human HNF4α2 in HepG2 cells</i>	156
4.3.2. <i>The UGT1A9 promoter -372 to -360 HNF4α-binding site is not necessary for the UGT1A9 promoter response to human HNF4α2</i>	156
4.3.3. <i>The UGT1A9 response to HNF4α in vitro is dependent on a second HNF4α-binding element</i>	158
4.3.4. <i>The UGT1A9 proximal promoter response to HNF4 requires HNF1α</i>	160
4.3.5. <i>A second HNF1 site is essential for synergistic regulation of the UGT1A9 promoter by HNF1α and HNF4α</i>	164
4.3.6. <i>Additional evidence for a direct interaction of HNF4α with UGT1A9</i>	167
4.3.7. <i>Nucleotide substitutions in the second HNF4 and HNF1 sites may partly explain the uniqueness of the UGT1A9 promoter response to HNF4α</i>	175
4.3.8. <i>The UGT1A9 initiator-like region contributes to its HNF4α-response</i>	176

4.3.9.	<i>HNF1β supports activation of the UGT1A9 promoter by HNF4α</i>	179
4.3.10.	<i>Differences between published work and this study are not explained by usage of HNF4α1 or the UGT1A9 T-275A polymorphism</i>	181
4.4	General discussion and summary	186
4.4.1.	<i>Achievement of aims</i>	186
4.4.2.	<i>Future directions</i>	187
4.4.3.	<i>Relevance to glucuronidation in humans</i>	191
4.4.4.	<i>Summary</i>	196

Chapter Five: Regulation of Endogenous UGT Expression in HEPG2 Cells

by Liver-Enriched Transcription Factors..... 197

5.1	Introduction	197
5.1.1.	<i>Promoter-reporter assays versus endogenous gene expression</i>	197
5.1.2.	<i>Aims</i>	198
5.1.3.	<i>Rationale</i>	200
5.2	Methods	219
5.2.1.	<i>Generation of liver-enriched transcription factor expression plasmids</i>	219
5.2.2.	<i>Transfection of HepG2 cells and extraction of total RNA</i>	220
5.2.3.	<i>Trichostatin A treatment of HepG2 cells</i>	220
5.2.4.	<i>Rifampicin treatment of HepG2 cells</i>	220
5.2.5.	<i>Reverse transcription and quantitative real-time PCR</i>	221
5.2.6.	<i>Cloning of the UGT1A3-9.4k and UGT1A4-5k promoters</i>	225
5.2.7.	<i>Transfection of HepG2 cells and dual-luciferase assay</i>	228
5.2.8.	<i>Hepatocyte nuclear factor 1α Western blot</i>	228
5.3	Results and discussion	228
5.3.1.	<i>Validation of 18S rRNA as a suitable internal control for HepG2 cells over-expressing liver-enriched transcription factors and/or treated with trichostatin A or rifampicin</i>	228
5.3.2.	<i>Basal levels of UGT1A and UGT2B mRNA transcripts in HepG2 cells</i>	231
5.3.3.	<i>Effect of rifampicin-liganded pregnane X receptor on endogenous UGT expression in HepG2 cells</i>	234
5.3.4.	<i>UGT1A3 promoter-reporter constructs lack ligand-dependent PXR responsiveness in HepG2 cells</i>	237
5.3.5.	<i>Effect of trichostatin A treatment on endogenous UGT expression in HepG2 cells</i>	241

5.3.6.	<i>Effect of trichostatin A treatment on endogenous expression of HNF1α in HepG2 cells</i>	247
5.3.7.	<i>Effect of over-expressed liver-enriched transcription factors on endogenous UGT expression in HepG2 cells</i>	250
5.3.8.	<i>Validation of the FoxA2 and C/EBPβ expression vectors</i>	283
5.4	General discussion and summary	285
5.4.1.	<i>Achievement of aims</i>	285
5.4.2.	<i>Broader directions for future investigations</i>	286
5.4.3.	<i>Relevance to pharmacogenetics and disease</i>	293
5.4.4.	<i>Summary</i>	295
Chapter Six: Genetic Determinants of Human UGT1A3 Expression.....		296
6.1	Introduction	296
6.1.1.	<i>Genetic variation in human UGT genes</i>	296
6.1.2.	<i>HNF1α gene polymorphisms in humans</i>	297
6.1.3.	<i>Aims</i>	299
6.2	Methods	300
6.2.1.	<i>Amplification of UGT1A3 sequences from genomic DNA</i>	300
6.2.2.	<i>HNF1α expression vectors</i>	302
6.2.3.	<i>Transient transfection and luciferase reporter assay</i>	302
6.2.4.	<i>Statistical analysis</i>	302
6.3	Results and discussion.....	302
6.3.1.	<i>The UGT1A3 promoter contains multiple SNPs, resulting in five alleles</i> ...	302
6.3.2.	<i>Activities of the newly defined UGT1A3 promoter alleles in vitro</i>	305
6.3.3.	<i>Regulation of the UGT1A3 promoter by HNF1α variants</i>	309
6.3.4.	<i>The UGT1A3 Promoter 2 allele is under-represented in a colon cancer cohort and is associated with the W11R/V47A protein variant</i>	312
6.4	General discussion and summary	316
6.4.1.	<i>Achievement of aims</i>	316
6.4.2.	<i>Future directions</i>	316
6.4.3.	<i>Relevance to pharmacogenetics</i>	318
6.4.4.	<i>Summary</i>	320
Chapter Seven: General Summary and Conclusions.....		322
7.1	Towards disease prevention and designer therapies.....	322
7.2	Summary of the research findings presented in this thesis.....	323

7.2.1.	<i>Chapter 3: In vitro characterisation of the UGT1A3, UGT1A4 and UGT1A5 proximal promoters</i>	323
7.2.2.	<i>Chapter 4: HNF1 transcription factors are essential for the UGT1A9 promoter response to HNF4α</i>	324
7.2.3.	<i>Chapter 5: Regulation of endogenous UGT expression in HepG2 cells by liver-enriched transcription factors</i>	324
7.2.4.	<i>Chapter 6: Genetic determinants of human UGT1A3 expression</i>	326
7.3	Relevant work published over the duration of this PhD candidature	327
7.4	Modelling human <i>UGT</i> gene regulation.....	329
7.5	Final remarks	330
	Appendix One: pGL3-Basic reporter vector map	332
	Appendix Two: pGL3+ reporter vector map	333
	Bibliography	334

LIST OF FIGURES

Figure 1.1:	Alternative metabolic pathways for 2-amino-1-methyl-6-phenylimidazo[4,5- <i>b</i>]pyridine (PhIP) after CYP activation, resulting in DNA adducts or detoxification.....	9
Figure 1.2:	Schematic representation of the glucuronidation reaction.....	11
Figure 1.3:	Dendrogram depicting relationships between the primary amino acid sequences of human UGTs.	13
Figure 1.4:	Schematic representation of the human <i>UGT1A</i> locus.	15
Figure 1.5:	Schematic representation of the human <i>UGT2</i> locus.....	16
Figure 1.6:	Excerpt from the current label for Camptosar (Irinotecan HCl), as obtained from the Food and Drug Administration website.	41
Figure 1.7:	Idealised structure of an eukaryotic gene.	46
Figure 1.8:	The <i>UGT1A</i> and <i>UGT2B</i> core promoters showing putative TATA box and initiator-like elements.	49
Figure 3.1:	Successive deletion constructs of the <i>UGT1A3</i> and <i>UGT1A4</i> promoters reveal positive regulatory elements necessary for basal activity.	106
Figure 3.2:	The human <i>UGT1A3</i> , <i>UGT1A4</i> and <i>UGT1A5</i> promoters contain putative HNF1-binding sites.....	109
Figure 3.3:	The HNF1-binding site is required for maximal basal activity of the <i>UGT1A3</i> and <i>UGT1A4</i> proximal promoters.	110
Figure 3.4:	HNF1 α from HepG2 nuclear extracts binds to nucleotides -156 to -128 of the <i>UGT1A3</i> and <i>UGT1A4/UGT1A5</i> promoters.	112
Figure 3.5:	HNF1 α from Caco-2 nuclear extracts binds to nucleotides -156 to -128 of the <i>UGT1A3</i> and <i>UGT1A4/UGT1A5</i> promoters.	113
Figure 3.6:	Activation of the <i>UGT1A3</i> -500bp promoter by HNF1 β in HEK293T cells.....	116
Figure 3.7:	Mutation of the <i>UGT1A3</i> HNF1-binding site to the equivalent <i>UGT1A4</i> sequence does not confer HNF1-responsiveness in HepG2 cells.....	118
Figure 3.8:	The <i>UGT1A3</i> -200 to -150bp region contains at least two regulatory elements that can positively influence transcription in HepG2 cells.....	120
Figure 3.9:	Characterisation of the <i>UGT1A3</i> promoter site 1 regulatory element.	121
Figure 3.10:	The <i>UGT1A3</i> and <i>UGT1A4</i> -200 to -150bp regions contain at least two regulatory elements that can positively influence their HNF1 α -response in HEK293T cells.	125
Figure 4.1:	Alignment of the -391 bp <i>UGT1A9</i> proximal promoter with the corresponding regions of <i>UGT1A7</i> , <i>UGT1A8</i> and <i>UGT1A10</i>	131
Figure 4.2:	Over-expression of human HNF4 α in HepG2 cells strongly up-regulates the human <i>UGT1A9</i> proximal promoter.....	157

Figure 4.3:	Assessment of HNF4 α binding to <i>UGT1A9</i> promoter sequences <i>in vitro</i>	159
Figure 4.4:	HNF1 α synergistically regulates the <i>UGT1A9</i> promoter with HNF4 α through a second HNF1-binding site.	161
Figure 4.5:	HNF1 α only moderately increases activation of the <i>UGT1A9</i> proximal promoter by HNF4 α in HepG2 cells.	163
Figure 4.6:	Mutation of a second putative HNF1-binding site decreases the co-operative activation of the <i>UGT1A9</i> proximal promoter by HNF1 α and HNF4 α in HEK293T cells.	165
Figure 4.7:	The second <i>UGT1A9</i> HNF1-response element binds HNF1 α <i>in vitro</i>	166
Figure 4.8:	Alignment of the oestrogen receptor β and HNF4 α DNA-binding domains.	169
Figure 4.9:	The HNF4 α R127W, DG69/70AA and RR76/77AE mutants have decreased ability to up-regulate the <i>UGT1A9</i> promoter <i>in vitro</i>	170
Figure 4.10:	Expression and binding capacity of wild-type and mutant HNF4 α proteins <i>in vitro</i>	172
Figure 4.11:	<i>S</i> -nitroso- <i>N</i> -acetyl penicillamine (SNAP) treatment decreases the ability of HNF4 α to up-regulate the <i>UGT1A9</i> promoter in HepG2 cells.	173
Figure 4.12:	Introduction of the <i>UGT1A9</i> HNF1s2 and HNF4s2 elements into the <i>UGT1A8</i> promoter does not confer HNF4 α -responsiveness to pGL3-1A8-2k.	177
Figure 4.13:	The Inr-like region of <i>UGT1A9</i> is more supportive of HNF4 α -responsiveness than the equivalent region of <i>UGT1A8</i>	178
Figure 4.14:	HNF1 β facilitates regulation of the <i>UGT1A9</i> proximal promoter by HNF4 α	180
Figure 4.15:	Comparison of human HNF4 α 2, human HNF4 α 1 and rat HNF4 α 1 pCMX expression vectors for effectiveness against the <i>UGT1A9</i> promoter.	183
Figure 4.16:	The <i>UGT1A9</i> -275 SNP decreases stimulation of the <i>UGT1A9</i> promoter by HNF4 α 2 <i>in vitro</i>	186
Figure 5.1:	All known human <i>UGT1A</i> and <i>UGT2B</i> promoters contain putative HNF1-binding sites.	204
Figure 5.2:	18S rRNA levels in treated HepG2 cells as a proportion of total extracted RNA.	230
Figure 5.3:	Expression of UGT mRNA in HepG2 cells under basal culture conditions.	233
Figure 5.4:	Endogenous UGT mRNA levels in HepG2 cells treated with 10 μ M rifampicin and/or over-expressed pregnane X receptor.	235
Figure 5.5:	PXR up-regulates the <i>UGT1A3</i> and <i>UGT1A4</i> promoters <i>in vitro</i> in a ligand-independent manner.	238
Figure 5.6:	Effects of trichostatin A on UGT mRNA levels in HepG2 cells.	243
Figure 5.7:	Effect of ethanol, trichostatin A and pCMX-HNF1 α on the levels of HNF1 α in HepG2 cells.	249

Figure 5.8A-C:	Effect of over-expressed liver-enriched transcription factors on endogenous UGT1A1, UGT1A3 and UGT1A4 expression in HepG2 cells.....	251
Figure 5.8D-F:	Effect of over-expressed liver-enriched transcription factors on endogenous UGT1A6, UGT1A7 and UGT1A9 expression in HepG2 cells.....	252
Figure 5.8G-I:	Effect of over-expressed liver-enriched transcription factors on endogenous UGT2B4, UGT2B7 and UGT2B10 expression in HepG2 cells.....	253
Figure 5.8J-L:	Effect of over-expressed liver-enriched transcription factors on endogenous UGT2B11, UGT2B15 and UGT2B17 expression in HepG2 cells.	254
Figure 5.8M:	Effect of over-expressed liver-enriched transcription factors on endogenous UGT2B28 expression in HepG2 cells.	255
Figure 5.9:	The <i>UGT1A3</i> and <i>UGT1A4</i> promoter responses to TSA and HNF1 α	262
Figure 5.10:	Response of the <i>UGT1A6</i> proximal promoter to HNF1 α and HNF4 α in HepG2 cells.	264
Figure 5.11:	HNF6 regulates the transiently transfected <i>UGT1A4</i> promoter in HepG2 cells.	274
Figure 5.12:	The pCMX-FoxA2 and pCMX-C/EBP β expression plasmids are active in HepG2 cells.....	284
Figure 6.1:	Alternative <i>UGT1A3</i> promoter alleles vary less than 1.4-fold in basal activity.	306
Figure 6.2:	Alternative <i>UGT1A3</i> promoter alleles are not decreased in their ability to respond to over-expressed HNF1 α	307
Figure 6.3:	Known HNF1 α protein variants are insufficient to explain the variability of UGT1A3 mRNA levels in humans.	310
Figure 6.4:	Two <i>UGT1A3</i> promoter variants interact with the tested HNF1 α protein variants similarly to the <i>UGT1A3</i> reference promoter sequence.	311

LIST OF TABLES

Table 1.1:	Human UDP-Glucuronosyltransferases and selected substrates.	18
Table 1.2:	Distribution of UDP-Glucuronosyltransferase mRNA in humans.	22
Table 2.1:	Reagents used in experimental procedures.	55
Table 2.2:	Primers used for cloning transcription factor cDNAs.	83
Table 3.1:	Primers used for cloning the <i>UGT1A3-1A5</i> proximal promoters, and in generating deleted or mutated promoter-reporter constructs.	100
Table 3.2:	Oligonucleotides used for EMSA and super-shift experiments.	105
Table 4.1:	Primers used in generating pGL3+, in cloning the <i>UGT1A7</i> , <i>UGT1A9</i> and <i>apoCIII</i> proximal promoters, and in generating deleted and mutated promoter-reporter and transcription factor expression constructs.	147
Table 4.2:	Oligonucleotides used for EMSA and super-shift experiments.	155
Table 5.1:	Primers and annealing conditions used for quantification of human UGT and 18S RNA transcripts.	222
Table 6.1:	Primers used in amplifying and cloning the human <i>UGT1A3</i> proximal promoter from genomic DNA samples.	301
Table 6.2:	Single nucleotide polymorphisms detected in a German population.	304
Table 6.3:	Association of <i>UGT1A3</i> promoter genotype with colon cancer.	313

SUMMARY

The UDP-glucuronosyltransferases (UGTs) are a superfamily of enzymes that glucuronidate small, lipophilic molecules, thereby altering their biological activity and excretion. In humans, important examples of UGT substrates include molecules of both endogenous and xenobiotic origin; thus, UGTs are considered essential contributors to homeostatic regulation and an important defence mechanism against chemical insult. In keeping with both roles, UGTs are most strongly expressed in the liver, a predominant organ involved in detoxification.

Rates of glucuronidation in humans are neither uniform among individuals, nor constant in an individual over time. Genetic determinants and non-endogenous signals are both known to influence the expression of UGTs, which in turn may affect the efficacy of certain pharmaceutical treatments or alter long-term risk of developing disease. Thus, this thesis focuses on the transcriptional regulation of *UGT* genes in humans, particularly on mechanisms that are likely to be relevant to their expression and variation in the liver. Two major approaches were used: firstly, extensive studies of several *UGT* promoters were performed to identify and characterise transcriptional elements that are important for UGT expression; and secondly, important hepatic transcription factors were investigated as potential regulators of *UGT* genes.

UGT1A3, *UGT1A4* and *UGT1A5* are a subset of highly related, but independently regulated, genes of the human *UGT1* subfamily. *UGT1A3* and *UGT1A4* are expressed in the liver, whereas *UGT1A5* is not. The presented analysis of the *UGT1A3*, *UGT1A4* and *UGT1A5* proximal promoters demonstrates that a hepatocyte nuclear factor (HNF)1-binding site common to all three promoters is important for

UGT1A3 and *UGT1A4* promoter activity *in vitro*, but is insufficient to drive *UGT1A5* expression. Two additional elements required for the maximal activity of the *UGT1A3* promoter were also identified that may distinguish this gene from *UGT1A4*. *UGT1A3* was investigated further, focusing on mechanisms that may contribute to interindividual variation in *UGT1A3* expression. Polymorphisms in the *UGT1A3* proximal promoter were identified and their functional consequences tested. Known variants of HNF1 α were also tested for altered activity towards the *UGT1A3* gene.

UGT1A9 is the only hepatic member of the *UGT1A7-1A10* subgroup of *UGT1* enzymes. Previous work had identified HNF1-binding sites in all four genes, and HNF4 α as an *UGT1A9*-specific regulator. The work presented herein extends these findings to show that HNF1 factors and HNF4 α synergistically regulate *UGT1A9*, and that HNF4 α is not the only transcription factor responsible for the unique presence of *UGT1A9* in the liver.

Liver-enriched transcription factors screened as potential *UGT* regulators were chosen from the HNF1, HNF4, HNF6, FoxA and C/EBP protein families. Functional interactions newly identified by this work were HNF4 α with *UGT1A1* and *UGT1A6*, HNF6 with *UGT1A4* and *UGT2B11*, FoxA1 and FoxA3 with *UGT2B11*, *UGT2B15* and *UGT2B28* and C/EBP α with *UGT2B17*. Observations were also made regarding different patterns of interaction between each *UGT* and the transcription factors tested, particularly HNF1 α .

These studies significantly advance the understanding of the transcriptional control of human *UGT* genes. In time, it is hoped that a detailed knowledge of *UGTs* will be useful in developing better therapeutic and prophylactic medical treatments.

DECLARATION

I certify that this thesis does not incorporate without acknowledgement any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Dione Gardner-Stephen

ACKNOWLEDGEMENTS

I wish to convey sincere, heartfelt gratitude to all those who have made this thesis possible. Whether specifically listed below or otherwise, your encouragement, support, feedback and sacrifices have been invaluable; I am and continue to be most grateful.

Firstly, I offer profuse thanks to my supervisor, Professor Peter Mackenzie. Thank you for not only encouraging me to take on this project, but also for following through with friendly, effective guidance and constant availability. I have long admired your ability to balance excellent science with other important commitments, especially your family.

Also to my other colleagues, both past and present, I owe a great debt of thanks for their work and friendship. In particular, I thank Dr. Rikke Lewinsky and Dr. Philip Gregory, for providing much of the groundwork on which this thesis is built. Extra thanks are also due to Phil for teaching me many of the techniques used in this project. I am also grateful to Anne Rogers and Joanna Treloar for their excellent technical assistance, to Heather Aubert and Karli Goodwin for their unsurpassed administrative support, and to the numerous other friends and colleagues in the Department of Clinical Pharmacology who have made my PhD candidature a pleasant and productive one.

To my husband, best friend and co-PhD-student, Paul, I am forever grateful. Your love, support, encouragement and (worn out) listening ear mean more to me than words could ever express. I love you dearly and I hope you find some use for all the molecular biology you have accidentally learnt in the last few years! To our unborn child, I owe the great debt of motivation: your impending arrival was a great

incentive to finish this thesis and a very welcome distraction from the more mundane aspects of “writing-up”. I also want to recognise the contributions that my immediate and extended family, my friends and my church family have all made to my well-being over the course of my PhD. Thank you to you all. Finally, I willingly acknowledge the claim that Christ has on my life and praise Him for His unfailing provision for me; past, present and future.

PUBLICATIONS ARISING DIRECTLY FROM THIS THESIS

Gardner-Stephen, D.A. and Mackenzie, P.I. (2007) Isolation of the UDP-glucuronosyltransferase 1A3 and 1A4 proximal promoters and characterization of their dependence on the transcription factor hepatocyte nuclear factor 1alpha. *Drug Metab. Dispos.* **35**: 116-120.

Gardner-Stephen, D.A. and Mackenzie, P.I. (2007) Hepatocyte nuclear factor 1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha. *Pharmacogenet. Genomics* **17**: 25-36.

Gardner-Stephen, D.A. and Mackenzie, P.I. (2005) Identification and characterisation of functional hepatocyte nuclear factor 1 binding sites in UDP-glucuronosyltransferase genes. *Methods Enzymol.* **400**: 22-46.

ADDITIONAL PUBLICATIONS RELATED TO THIS THESIS

Gregory, P.A. **Gardner-Stephen, D.A.**, Rogers, A., Michael, M.Z., and Mackenzie, P.I. (2006) The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter. *Pharmacogenet. Genomics* **16**: 527-536.

Finel M., Li X., **Gardner-Stephen D.A.**, Bratton S., Mackenzie P.I. and Radomska-Pandya A. (2005) Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity. *J. Pharmacol. Exp. Ther.* **315**: 1143-1149.

Mackenzie P.I., Gregory P.A., Lewinsky R.H., Yasmin S.N., Height T., McKinnon R.A. and **Gardner-Stephen D.A.** (2005) Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltransferases. *Toxicol. Appl. Pharmacol.* **207**: S77-83.

Gregory P.A., Lewinsky R.H., **Gardner-Stephen D.A.** and Mackenzie P.I. (2004) Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. *Toxicol. Appl. Pharmacol.* **199**: 354-363.

Gregory P.A., Lewinsky R.H., **Gardner-Stephen D.A.** and Mackenzie P.I. (2004) Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2. *Mol. Pharmacol.* **65**: 953-963.

Uchaipichat V., Mackenzie P.I., Guo X.H., **Gardner-Stephen D.A.**, Galetin A., Houston J.B. and Miners J.O. (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation,

effects of organic solvents, and inhibition by diclofenac and probenecid. *Drug Metab. Dispos.* **32**: 413-423.

Gardner-Stephen D.A., Heydel J.M., Goyal A., Lu Y., Xie W., Lindblom T., Mackenzie P.I. and Radomska-Pandya A. (2004) Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. *Drug Metab. Dispos.* **32**: 340-347.

Gregory P.A., **Gardner-Stephen D.A.**, Lewinsky R.H., Duncliffe K.N. and Mackenzie P.I. (2003) Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an initiator-like region. *J. Biol. Chem.* **278**: 36107-36114.

Mackenzie P.I., Gregory P.A., **Gardner-Stephen D.A.**, Lewinsky R.H., Jorgensen B.R., Nishiyama T., Xie W. and Radomska-Pandya A. (2003) Regulation of UDP glucuronosyltransferase genes. *Curr. Drug Metab.* **4**: 249-257.

AWARDS IN SUPPORT OF THIS THESIS

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Percy Student Poster Prize: Australian Health and Medical Research Congress 2004.

Australian Society for Biochemistry and Molecular Biology Student Poster Prize: ComBio2005 Combined National Conference 2005.

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Peter Meffin Student Poster Prize (honourable mention): National Joint Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Australasian Pharmaceutical Science Association 2005.

Outstanding Laboratory Research Presentation Oral Prize: Flinders Cancer Control Alliance Research Day 2007.

ABBREVIATIONS

ADH	alcohol dehydrogenase
AF	activation function
AhR	aryl hydrocarbon receptor
apo	apolipoprotein
ATCC	American Type Culture Collection
ATP	adenosine triphosphate
BAC	bacterial artificial chromosome
β -ME	β -mercaptoethanol
BSA	bovine serum albumin
bZIP	basic region leucine zipper
C/EBP	CCAAT/enhancer binding protein
CAR	constitutive androstane receptor
CBP	CREB-binding protein
CDCA	chenodeoxycholic acid
Cdx	caudal-related homeodomain protein
CIP	calf intestinal alkaline phosphatase
CMV	cytomegalovirus
CoA	coenzyme A
cpm	counts per minute
CREB	cAMP-response-element-binding protein
CYP	cytochrome P450
DBP	D-site binding protein
DCoH	dimerisation co-factor of HNF1
DD	dihydrodiol dehydrogenase
DMEM	Dulbecco's modified Eagle's medium
DMSO	dimethyl sulphoxide
dNTP	deoxynucleotide-triphosphate
DTT	dithiothreitol
<i>E. coli</i>	<i>Escherichia coli</i>
EDTA	ethylenediaminetetra-acetic acid
EMSA	electrophoretic mobility-shift assay
ER β	oestrogen receptor β
fabp	fatty acid-binding protein
FoxA	forkhead box A
FXR	farnesoid X receptor
glut2	glucose transporter 2
GR	glucocorticoid receptor
GRIP	glucocorticoid receptor interacting protein
HAT	histone acetyltransferase
HCV	hepatitis C virus
HDAC	histone deacetylase
HNF	hepatocyte nuclear factor
IL	interleukin
Inr	initiator
LAP	liver-enriched transcriptional activator protein
LB	Luria broth

LETF	liver-enriched transcription factor
LIP	liver-enriched transcriptional inhibitory protein
LXR	liver X receptor
MODY	mature onset diabetes of the young
MRP	multidrug resistance protein
NCoR	nuclear receptor co-repressor
NNAL	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
NRRE	nuclear receptor response element
NSAID	non-steroidal anti-inflammatory drug
OAT	organic anion transporter
Oct	octamer transcription factor
P/CAF	p300/CBP-associated factor
PBREM	phenobarbital response enhancer module
PBS	phosphate buffered saline
pBSII	pBlueScript II
PCR	polymerase chain reaction
PGC	PPAR-gamma co-activator
PhIP	2-amino-1-methyl-6-phenylimidazo[4,5- <i>b</i>]pyridine
POU	Pit-1, Oct-1 and Oct-2, and Unc-86
PPAR	peroxisome-proliferator-activated receptor
PXR	pregnane X receptor
QPCR	quantitative real-time PCR
rRNA	ribosomal RNA
rs	reference SNP
RXR	retinoid X receptor
SDS	sodium dodecyl sulphate
SHP	small heterodimer partner
siRNA	small interfering RNA
SMP	skim milk powder
SMRT	silencing mediator of retinoid and thyroid hormone receptor
SN-38	7-ethyl-10-hydroxycamptothecine
SNAP	<i>S</i> -nitroso- <i>N</i> -acetyl penicillamine
SNP	single nucleotide polymorphism
SRC	steroid receptor co-activator
TBE	tris-borate EDTA
TBST	tris-buffered saline/tween-20
TFII	transcription factor II
Tris	tris[hydroxymethyl]aminomethane
TSA	trichostatin A
TSS	transcription start site
UDP	uridine diphosphate
UGT	UDP-glucuronosyltransferase
XRE	xenobiotic response element